Pacific Edge reviews US pricing for new Cxbladder test, trading halted

Pacific Edge reviews US pricing for new Cxbladder test, trading halted
Pacific Edge says Cxbladder Triage Plus delivers “significant performance improvements” compared to its existing tests. (Image: Pacific Edge)
Rebecca Howard
Pacific Edge has been placed on a trade halt while it reviews draft gapfill or reimbursement rates for its new Cxbladder Triage Plus test from the US Centres for Medicare and Medicaid Services.“[It said it's] reviewing the prices and the associated documentation and needs time to assess the implications of them, consult with its advisers and industry partners, and prepare an announcement that provides context to investors.”Gapfill prices are proposed reimbursement rates for new or unpriced clinical diagnostic laboratory tests.Th...

More Markets

Air NZ to airports: Stop subsidising Jetstar
Markets

Air NZ to airports: Stop subsidising Jetstar

Current airport regulation works against the national interest, Air NZ’s new CEO says.

Genesis sets out gas strategy
Markets

Genesis sets out gas strategy

Storage, Kupe’s long-term role and LNG flexibility anchor the plan.

RBNZ data scotches Dosh claims of bank registration application
Finance

RBNZ data scotches Dosh claims of bank registration application

The regulator received no bank-registration applications in July 2024. 

Ports owned by councils ‘underperform’: time to list?
Markets

Ports owned by councils ‘underperform’: time to list?

There is clear evidence that listing leads to better businesses, market experts say.